Abstract
Hypokalaemia (defined as a plasma potassium concentration < 3.5 mEq/L) is a common electrolyte abnormality in clinical practice. Drugs are a common cause of either asymptomatic or symptomatic hypokalaemia. Drug-induced hypokalaemia is an important problem particularly in the elderly and in patients with cardiovascular, renal or hepatic disease. Hypokalaemia can complicate the use of the drug in the therapeutic concentration range, and can also be precipitated with overdose or conditions leading to drug intoxication. Because the etiologies of hypokalaemia are numerous, the diagnosis of drug-induced hypokalaemia may be overlooked. Physicians should always pay close attention to this common side effect. Evaluation and management of a hypokalaemic patient should include a careful review of medications history to determine if a drug capable of causing or aggravating this electrolyte abnormality is present.
Current Drug Safety
Title: Drug-Induced Hypokalaemia
Volume: 4 Issue: 1
Author(s): Chaker Ben Salem, Houssem Hmouda and Kamel Bouraoui
Affiliation:
Abstract: Hypokalaemia (defined as a plasma potassium concentration < 3.5 mEq/L) is a common electrolyte abnormality in clinical practice. Drugs are a common cause of either asymptomatic or symptomatic hypokalaemia. Drug-induced hypokalaemia is an important problem particularly in the elderly and in patients with cardiovascular, renal or hepatic disease. Hypokalaemia can complicate the use of the drug in the therapeutic concentration range, and can also be precipitated with overdose or conditions leading to drug intoxication. Because the etiologies of hypokalaemia are numerous, the diagnosis of drug-induced hypokalaemia may be overlooked. Physicians should always pay close attention to this common side effect. Evaluation and management of a hypokalaemic patient should include a careful review of medications history to determine if a drug capable of causing or aggravating this electrolyte abnormality is present.
Export Options
About this article
Cite this article as:
Salem Ben Chaker, Hmouda Houssem and Bouraoui Kamel, Drug-Induced Hypokalaemia, Current Drug Safety 2009; 4 (1) . https://dx.doi.org/10.2174/157488609787354369
DOI https://dx.doi.org/10.2174/157488609787354369 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Protective Effect of Natural Antioxidants on Heart Against Ischemia-Reperfusion Damage
Current Pharmaceutical Biotechnology Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Prognostic Value of White Blood Cell Counts and C-reactive Protein in Acute Ischemic Stroke Patients After Intravenous Thrombolysis
Current Neurovascular Research Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Biomarkers of Aspirin Resistance
Recent Patents on Biomarkers Editorial: Time for Earlier and More Intensive Preventive Therapy
Current Vascular Pharmacology Editorial [Hot Topic: One Century of Triglycerides, but there is Still Lots to Learn(Guest Editors: K. Anagnostopoulou, D.P. Mikhailidis and G. Kolovou)]
Current Drug Targets Meet Our Section Editor
Current Vascular Pharmacology The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
CNS & Neurological Disorders - Drug Targets Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease (COPD): Focus on Virus Induced Exacerbations
Current Pharmaceutical Design Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens
Current HIV Research Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity
Current Pharmaceutical Design Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?
Current Vascular Pharmacology Prevention of Cardiovascular Diseases with Anti-Inflammatory and Anti- Oxidant Nutraceuticals and Herbal Products: An Overview of Pre-Clinical and Clinical Studies
Recent Patents on Inflammation & Allergy Drug Discovery